Chromogenic peptide substrate assays and their clinical applications.
Chromogenic peptide substrates were first introduced into research laboratories in the early 1970s and were quickly utilised to develop assays for the determination of enzymes, proenzymes and inhibitors of the coagulation system. These assays were gradually introduced into coagulation and clinical chemistry laboratories as laboratory tools in the diagnosis and treatment of coagulation disorders. From the knowledge of the structures of the natural substrates attacked by enzymes other than those of the coagulation system or by synthesis and random screening, substrates for enzymes of the fibrinolytic, plasma and glandular kallikrein and complement systems were produced. These allowed various research groups to develop assays for components of these systems and subsequently led to the use of these assays in studies on various clinical conditions. Substrates for activated protein C ensured that assays for this enzyme and its inhibitors could be developed and introduced into the haematological routine. With the introduction of substrates for limulus lysate not only were assays for endotoxins in clinical samples produced but the control of all disposable products and injectables for endotoxin contamination can now be effected. Initially high costs and time-consuming manual assays were a hinderence to the general acceptance of the use of chromogenic peptide substrate assays and they were only used routinely in a few specialised laboratories. With the introduction of automated and microtitre plate methods however, these assays are are now available in most hospital laboratories. Since the first chromogenic peptide substrate was described thousands of articles have been published on the use of chromogenic substrate assays to measure proenzymes, enzyme activators, enzyme cofactors and inhibitors in blood and other body fluids in normal subjects and clinical material. We have endeavoured to cover as many of these as possible in this review.
Gallimore
M J
MJ
Channel Diagnostics, Deal, Kent, UK.
Friberger
P
P
D001774:Blood Chemical Analysis / Q000379:methods*; D001780:Blood Coagulation Tests; D001798:Blood Proteins / Q000032:analysis; D001826:Body Fluids / Q000737:chemistry*; D002315:Cardiopulmonary Bypass; D002863:Chromogenic Compounds; D003167:Complement Activation; D003422:Critical Care; D004066:Digestive System Diseases / Q000097:blood; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000032:analysis; D004792:Enzyme Precursors / Q000032:analysis; D004798:Enzymes / Q000032:analysis; D006084:Graft Rejection; D006402:Hematologic Diseases / Q000097:blood; D006801:Humans; D007388:Internal Medicine; D004364:Pharmaceutical Preparations / Q000032:analysis; D011786:Quality Control
D001798:Blood Proteins; D002863:Chromogenic Compounds; D004791:Enzyme Inhibitors; D004792:Enzyme Precursors; D004798:Enzymes; D004364:Pharmaceutical Preparations